Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report

Celeste Witting; Jessica Quaggin-Smith; Ruben Mylvaganam; Graham Peigh; Michael Angarone; James D. Flaherty

doi:10.1016/j.diagmicrobio.2020.115272

Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report

Celeste Witting, Jessica Quaggin-Smith, Ruben Mylvaganam, Graham Peigh, Michael Angarone, James D. Flaherty^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy.

Original language	English (US)
Article number	115272
Journal	Diagnostic Microbiology and Infectious Disease
Volume	99
Issue number	4
DOIs	https://doi.org/10.1016/j.diagmicrobio.2020.115272
State	Published - Apr 2021

Keywords

COVID-19
aspergillosis
fungal infections
opportunistic Infections
pulmonary disease
tocilizumab

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.diagmicrobio.2020.115272

Cite this

@article{0e1f10a288fa45d5bfff4c13ea611351,

title = "Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report",

abstract = "Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy.",

keywords = "COVID-19, aspergillosis, fungal infections, opportunistic Infections, pulmonary disease, tocilizumab",

author = "Celeste Witting and Jessica Quaggin-Smith and Ruben Mylvaganam and Graham Peigh and Michael Angarone and Flaherty, {James D.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2021",

month = apr,

doi = "10.1016/j.diagmicrobio.2020.115272",

language = "English (US)",

volume = "99",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS

T2 - a case report

AU - Witting, Celeste

AU - Quaggin-Smith, Jessica

AU - Mylvaganam, Ruben

AU - Peigh, Graham

AU - Angarone, Michael

AU - Flaherty, James D.

PY - 2021/4

Y1 - 2021/4

N2 - Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy.

AB - Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy.

KW - COVID-19

KW - aspergillosis

KW - fungal infections

KW - opportunistic Infections

KW - pulmonary disease

KW - tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=85098717731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098717731&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2020.115272

DO - 10.1016/j.diagmicrobio.2020.115272

M3 - Article

C2 - 33388572

AN - SCOPUS:85098717731

SN - 0732-8893

VL - 99

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 4

M1 - 115272

ER -

Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this